Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -75.78%. However, over the past six months, we’ve seen a stronger performance of -89.43%. The price of RSLS leaped by -76.87% over the last 30 days. And in the last five days, it has fallen by -61.58%.
In terms of market performance, ReShape Lifesciences Inc had a fairly uneven. The highest value for the stock in the past year was $29.00 on 05/29/24, and the lowest value was recorded at $2.32 on 02/18/25.
52-week price history of RSLS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. ReShape Lifesciences Inc’s current trading price is -96.28% away from its 52-week high, while its distance from the 52-week low is -53.45%. The stock’s price range during this period has varied between$2.32 and $29.00. The ReShape Lifesciences Inc’s shares, which operate in the Healthcare, saw a trading volume of around 5.86 million for the day, a figure considerably higher than their average daily volume of 38270.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
ReShape Lifesciences Inc (RSLS) has experienced a quarterly decline of -80.78% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 0.79M and boasts a workforce of 31 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.86, with a change in price of -6.91. Similarly, ReShape Lifesciences Inc recorded 159,372 in trading volume during the last 100 days, posting a change of -86.48%.
RSLS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RSLS stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.05.
RSLS Stock Stochastic Average
ReShape Lifesciences Inc’s raw stochastic average for the past 50 days is presently 1.50%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 1.89%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 0.89% and 2.40%, respectively.
